Fundación Valle de Lili, Cali, Colombia.
Universidad Icesi, Cali, Colombia.
Glob Heart. 2022 Aug 18;17(1):57. doi: 10.5334/gh.1145. eCollection 2022.
There is a lack of epidemiological data around heart failure (HF) in Latin America; the potential impact description of this disease in middle-income countries is relevant.
This study aimed to describe the characteristics and healthcare resource utilization patterns of HF patients at baseline and six-month follow-up.
This retrospective observational study used data from the RECOLFACA () registry, which includes data obtained from the examination of clinical records from 2,528 patients in 60 Colombian healthcare institutions. Baseline and six-month follow-up data were evaluated from patients with previous hospital admissions due to HF during the 12 months prior to enrollment.
This study analyzed 2,045 patients (42.8% female) with a mean age of 67.71 ± 13.64 years. The most common etiologies were ischemic (44.4%) and hypertensive heart disease (38.5%). At baseline, 53.4% of patients were classified with NYHA class II, and 73.6% had a reduced left ventricle ejection fraction (LVEF). A year prior to entering the registry, patients were hospitalized an average of 1.4 ± 1.1 times due to HF. Prescription of evidence-based treatment at baseline included sacubitril/valsartan (10%), ACEI (33%), ARB (41%), beta-blocker (79%), diuretics (68%), and MRA (56%). The average quality of life score measured using the EQ-5D-3L questionnaire was 78.7 ± 20.8 at baseline and 82.3 ± 20.1 at the six-month follow-up. The mortality rate was 6.7%.
The use of information from the RECOLFACA registry allowed characterization as well as analyses of healthcare resource utilization of patients with heart failure in Colombia. The results of this study show that multiple evidence-based treatments for HF are being widely used in Colombia, but there seems to be room for improvement regarding some interventions for the treatment of patients with HF.
拉丁美洲缺乏心力衰竭（HF）的流行病学数据；描述中低收入国家这种疾病的潜在影响具有相关性。
本研究旨在描述 HF 患者基线和 6 个月随访时的特征和医疗资源利用模式。
这是一项回顾性观察性研究，使用了来自 RECOLFACA（）登记处的数据，该登记处的数据来自 60 家哥伦比亚医疗机构的临床记录检查，共纳入了 2528 名患者。根据患者在登记前 12 个月内因 HF 住院的情况，评估了基线和 6 个月随访的数据。
本研究分析了 2045 名（42.8%为女性）患者，平均年龄为 67.71±13.64 岁。最常见的病因是缺血性（44.4%）和高血压性心脏病（38.5%）。基线时，53.4%的患者为 NYHA 心功能 II 级，73.6%的患者左心室射血分数（LVEF）降低。在进入登记处前一年，患者因 HF 平均住院 1.4±1.1 次。基线时，证据支持的治疗处方包括沙库巴曲缬沙坦（10%）、ACEI（33%）、ARB（41%）、β受体阻滞剂（79%）、利尿剂（68%）和 MRA（56%）。使用 EQ-5D-3L 问卷测量的平均生活质量评分，基线时为 78.7±20.8，6 个月随访时为 82.3±20.1。死亡率为 6.7%。
利用 RECOLFACA 登记处的信息，可以对哥伦比亚 HF 患者的特征和医疗资源利用情况进行描述和分析。本研究结果表明，HF 的多种证据支持的治疗方法在哥伦比亚得到了广泛应用，但在 HF 患者的某些治疗干预方面似乎还有改进的空间。
